Silence Therapeutics Management
Management criteria checks 2/4
Silence Therapeutics' CEO is Craig Tooman, appointed in Feb 2022, has a tenure of 2.75 years. total yearly compensation is £7.30M, comprised of 6.5% salary and 93.5% bonuses, including company stock and options. directly owns 0.024% of the company’s shares, worth $85.72K. The average tenure of the management team and the board of directors is 2.1 years and 4.8 years respectively.
Key information
Craig Tooman
Chief executive officer
UK£7.3m
Total compensation
| CEO salary percentage | 6.5% |
| CEO tenure | 2.8yrs |
| CEO ownership | 0.02% |
| Management average tenure | 2.1yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -UK£59m |
| Jun 30 2024 | n/a | n/a | -UK£40m |
| Mar 31 2024 | n/a | n/a | -UK£35m |
| Dec 31 2023 | UK£7m | UK£473k | -UK£43m |
| Sep 30 2023 | n/a | n/a | -UK£43m |
| Jun 30 2023 | n/a | n/a | -UK£41m |
| Mar 31 2023 | n/a | n/a | -UK£43m |
| Dec 31 2022 | UK£6m | UK£461k | -UK£40m |
| Sep 30 2022 | n/a | n/a | -UK£36m |
| Jun 30 2022 | n/a | n/a | -UK£39m |
| Mar 31 2022 | n/a | n/a | -UK£39m |
| Dec 31 2021 | UK£2m | UK£334k | -UK£39m |
Compensation vs Market: Craig's total compensation ($USD9.17M) is above average for companies of similar size in the US market ($USD2.24M).
Compensation vs Earnings: Craig's compensation has increased whilst the company is unprofitable.
CEO
Craig Tooman (59 yo)
2.8yrs
Tenure
UK£7,298,000
Compensation
Mr. Craig A. Tooman, MBA, serves as President, Chief Executive Officer and Executive Director of Silence Therapeutics plc since February 21, 2022. He has been a Supervisory Director of Curevac N. V. since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.8yrs | UK£7.30m | 0.024% $ 85.7k | |
| Executive VP | 2.8yrs | UK£2.50m | 0.0011% $ 3.8k | |
| Executive VP and Chief Research & Development Officer | 1.6yrs | UK£1.82m | 0.0092% $ 33.2k | |
| Chief Scientific Officer | less than a year | no data | no data | |
| Head of IR & Corporate Communications | no data | no data | no data | |
| Chief Human Resources Officer | less than a year | no data | no data | |
| Senior VP and Chief Intellectual Property & Innovation Officer | 2.2yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | 4.3yrs | no data | no data | |
| Chief Technical Operations Officer | 2yrs | no data | no data | |
| Chief Medical Officer | no data | no data | no data |
2.1yrs
Average Tenure
61yo
Average Age
Experienced Management: SLNC.F's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 2.8yrs | UK£7.30m | 0.024% $ 85.7k | |
| Independent Non-Executive Director | 6.4yrs | UK£184.00k | 0.0054% $ 19.3k | |
| Chairman of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Independent Non-Executive Director | 3.8yrs | UK£178.00k | 0.0092% $ 33.2k | |
| Independent Chairman of the Board | 5.6yrs | UK£402.00k | 0.078% $ 281.4k | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Independent Non-Executive Director | 5.6yrs | UK£182.00k | 0.011% $ 38.4k | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 4.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.8yrs | no data | no data |
4.8yrs
Average Tenure
62yo
Average Age
Experienced Board: SLNC.F's board of directors are considered experienced (4.8 years average tenure).